You are here: Industry Insights > ViiV

News List

ViiV unveils positive data for two-drug HIV regimens pharmatimes
July 26, 2018
ViiV Healthcare has unveiled positive clinical data for two two-drug HIV regimens ay the 22nd International AIDS conference in Amsterdam, showing long-term efficacy and non-inferiority to a current standard of care.
ViiV’s two-drug HIV regimen hits PhIII targets pharmatimes
July 06, 2018
ViiV Healthcare’s two-drug HIV regimen of Tivicay and Epivir has hit targets in late-stage trials, showing non-inferiority to a three-drug regimen and thus the potential to offer patients an alternative treatment strategy.
ViiV trials drug for HIV prevention in women pharmatimes
December 01, 2017
ViiV Healthcare has initiated a Phase III study exploring the efficacy of long-acting cabotegravir for the prevention of HIV infection in sexually active women.
ViiV reaches another milestone in the development of a long-acting HIV regimen pharmaceutical-technology
July 31, 2017
On July 24, 2017, ViiV Healthcare announced positive results from 96-week data obtained from a Phase IIb, open-label study (LATTE-2) investigating the safety and efficacy of a two-drug...
ViiV’s long-acting two-drug HIV regimen hits targets pharmatimes
July 26, 2017
A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial

Previous page 1 2 3 Next page